| Abstract: |
IntroductionPatients with pretreated relapsed/refractory multiple myeloma (RRMM) have a poor prognosis and limited treatment options, underscoring the need for safe treatments with durable efficacy.MethodsThis Phase 2 study evaluated magrolimab (Magro) plus daratumumab (Dara) or pomalidomide/dexamethasone (Pd) or carfilzomib/dexamethasone (Kd) in RRMM. The primary efficacy endpoint was objective response rate (ORR).ResultsORR was 14.3% (Magro+Dara; n = 14), 20.0% (Magro+Pd; n = 10) and 36.4% (Magro+Kd; n = 11). There were two dose-limiting toxicities: febrile neutropenia (Magro+Dara) and infusion-related reaction (Magro+Pd). Grade >= 3 Magro-related adverse event (AE) rates were 64.3% (Magro+Dara), 60.0% (Magro+Pd) and 63.6% (Magro+Kd). Two deaths were AE-related; neither was Magro related.ConclusionAs the study closed early, insights into the clinical profile of Magro combinations in RRMM are limited.Trial RegistrationThis trial was registered at www.clinicaltrials.gov as #NCT04892446 |
